An investigation of 0.05% cyclosporine ophthalmic emulsion in reducing ocular surface staining and impact on visual performance in individuals with dry eye

被引：0
|
作者：
Torkildsen, Gail [1 ]
Stonecipher, Karl [2 ]
Ousler, George W. [3 ]
Villanueva, Linda [4 ]
Hollander, David A. [4 ]
机构：
[1] Andover Eye, Andover, MA USA
[2] TLC Laser Eye Ctr, Greensboro, NC USA
[3] Ora Inc, Andover, MA USA
[4] Allergan Pharmaceut Inc, Irvine, CA 92715 USA
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2015年 / 56卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
4479
引用
收藏
页数：2
相关论文
共 16 条
  • [1] The IMPAPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye
    Stonecipher, Karl G.
    Torkildsen, Gail L.
    Ousler, George W., III
    Morris, Scot
    Villanueva, Linda
    Hollander, David A.
    CLINICAL OPHTHALMOLOGY, 2016, 10 : 887 - 895
  • [2] Evaluation of 0.05% Cyclosporine Ophthalmic Emulsion on Ocular Surface Staining and Visual Function in Subjects Who Experience Discomfort While Engaging in Electronic Visual Tasking
    Stonecipher, Karl
    Torkildsen, Gail
    McLaurin, Eugene B.
    Villanueva, Linda
    Ousler, George W.
    Hollander, David A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [3] Cyclosporine 0.05% ophthalmic emulsion for the treatment of radiation-associated dry eye in children
    Hoehn, Mary Ellen
    Kelly, Steven R.
    Wilson, Matthew W.
    Walton, R. Christopher
    PEDIATRIC BLOOD & CANCER, 2013, 60 (07) : E35 - E37
  • [4] Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
    Deveney, Tatiana
    Asbell, Penny A.
    CLINICAL OPHTHALMOLOGY, 2018, 12 : 569 - 576
  • [5] Restasis - Cyclosporine ophthalmic emulsion, 0.05% Allergan - Drug increases tear production in patients with chronic dry eye due to ocular inflammation
    不详
    FORMULARY, 2003, 38 (02) : 79 - 80
  • [6] Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
    Burade, Vinod
    Zalawadia, Rishit
    Patel, Alpesh
    Ogundele, Abayomi
    CLINICAL OPHTHALMOLOGY, 2020, 14 : 2747 - 2755
  • [7] CYCLOSPORINE OPHTHALMIC SOLUTION 0.09% IMPROVES THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE IN PATIENTS WHOSE DISEASE IS INADEQUATELY CONTROLLED ON CYCLOSPORINE OPHTHALMIC EMULSION 0.05%
    Johnston, J.
    Adler, R.
    Hessen, M.
    Nichols, K.
    Pflugfelder, S.
    Truett, K.
    Urbieta, M.
    Reynolds, R.
    VALUE IN HEALTH, 2024, 27 (06) : S32 - S32
  • [8] An evaluation of Retaine (TM) ophthalmic emulsion in the management of tear film stability and ocular surface staining in patients diagnosed with dry eye
    Ousler, George, III
    Devries, Douglas K.
    Karpecki, Paul M.
    Ciolino, Joseph B.
    CLINICAL OPHTHALMOLOGY, 2015, 9 : 235 - 243
  • [9] PERSIST: Physician's Evaluation of Restasis (R) Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review
    Mah, Francis
    Milner, Mark
    Yiu, Samuel
    Donnenfeld, Eric
    Conway, Taryn M.
    Hollander, David A.
    CLINICAL OPHTHALMOLOGY, 2012, 6 : 1971 - 1976
  • [10] A RETROSPECTIVE ANALYSIS OF REAL-WORLD TREATMENT PATTERNS IN PATIENTS OVER AGE 64 WITH DRY EYE DISEASE RECEIVING OTX-101 OPHTHALMIC SOLUTION 0.09%, CYCLOSPORINE OPHTHALMIC EMULSION 0.05%, OR LIFITEGRAST OPHTHALMIC SOLUTION 5%
    Karpecki, P.
    Barghout, V
    Schenkel, B.
    Huynh, L.
    Khanal, A.
    Mitchell, B.
    Yenikomshian, M.
    Zanardo, E.
    Matossian, C.
    VALUE IN HEALTH, 2023, 26 (06) : S337 - S337
12